References
1. Gonzalo-Gil E., Ikediobi U., Sutton R.E. Mechanisms of virologic control and clinical characteristics of HIV+ elite/viremic controllers. Yale J Biol Med. 2017; 90 (2) 245-59.
2. Gurdasani D.A., Iles L., Dillon D.G., et al. A systematic review of definitions of extreme phenotypes of HIV control and progression the UK HIV Genomics Consortium. AIDS. 2014; 28 (2): 149-62.
3. Grabar S., Selinger-Leneman H., Abgrall S., et al. Loss of long-term non-progressor and HIV controller status over time in the French Hospital Database on HIV - ANRS CO4. PLoS One. 2017; 12 (10): e0184441
4. Okulicz J.F., Marconi V.C., Landrum M.L., et al. Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. J Infect Dis. 2009; 200 (11): 1714-23.
5. Lambotte O., Boufassa F., Madec Y., et al. HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clin Infect Dis. 2005; 41 (7): 1053-6.
6. Grabar S., Selinger-Leneman H., Abgrall S., et al. Prevalence and comparative characteristics of long-term non-progressors and HIV controller patients in the French Hospital Database on HIV. AIDS. 2009; 23 (9): 1163-9.
7. Meijerink H., Indrati A.R., van Crevel R., et al. The number of CCR5 expressing CD4+ T lymphocytes is lower in HIV-infected long-term non-progressors with viral control compared to normal progressors: a cross-sectional study. BMC Infect Dis. 2014; 14: 683.
8. Smith M.W., Dean M., Carrington M., et al. Contrasting genetic influence of CCR2 and CCR5 variants on HIV-1 infection and disease progression. Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC), ALIVE Study. Science. 1997; 15 (277): 959-65.
9. Yan J., Sabbaj S., Bansal A., et al. HIV-specific CD8+ T cells from elite controllers are primed for survival. J Virol. 2013; 87 (9): 5170-81.
10. Slichter C.K., Friedrich D.P., Smith R.J., et al. Measuring inhibition of HIV replication by ex vivo CD8(+) T cells. J Immunol Methods. 2014; 404: 71-80.
11. Fellay J., Ge D., Shianna K.V., et al. Common genetic variation and the control of HIV-1 in humans. PLoS Genet. 2009; 5 (12): e1000791.
12. MacDonald K.S., Fowke K.R., Kimani J., et al. Influence of HLA supertypes on susceptibility and resistance to human immunodeficiency virus type 1 infection. J Infect Dis. 2000; 181 (5): 1581-9.
13. Santos J.S., Ribeiro C.E., Almeida S.M., et al. Clinical, virologic and immunological outcomes in a cohort of long-term non-progressor HIV infected patients, Southern Brazil. J AIDS Clin Res. 2015; 6 (9). doi: 10.4172/2155-6113.1000502
14. Bosinger S.E., Utay N.S. Type I interferon: understanding its role in HIV pathogenesis and therapy. Curr HIV/AIDS Rep. 2015; 12 (1): 41-53.
15. Palacios J.A., Perez-Pinar T., Toro C., et al. Long-term non-progressor and elite controller patients who control viremia have a higher percentage of methylation in their HIV-1 proviral promoters than aviremic patients receiving highly active antiretroviral therapy. J Virol. 2012; 86 (23): 13 081-4.
16. Nissen S., Christiansen M., Helleberg M., et al. Whole exome sequencing of HIV-1 long-term non-progressors identifies rare variants in genes encoding innate immune sensors and signaling molecules. Sci Rep. 2018; 8 (1): 15253.
17. Brenchley J.M., Price D.A., Schacker T.W., et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006; 12 (12): 1365-71.
18. Acchioni C., Marsili G., Perrotti E., et al. Type I IFN-a blunt spear in fighting HIV-1 infection. Cytokine Growth Factor Rev. 2015; 26 (2): 14358.
19. Freiberg, M. S., Chang C.H., Skanderson M., et al. Association between HIV infection and the risk of heart failure with reduced ejection fraction and preserved ejection fraction in the antiretroviral therapy era: results from the Veterans Aging Cohort Study. JAMA Cardiol. 2017; 2 (5): 536-46.
20. Deeks, S.G., Lewin S.R., Havlir D.V. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013; 382 (9903): 1525-33.
21. D’Ascenzo F., Cerrato E., Calcagno A., et al. High prevalence at computed coronary tomography of non-calcified plaques in asymptomatic HIV patients treated with HAART: a meta-analysis. Atherosclerosis. 2015; 240 (1): 197-204.
22. Hsue P.Y., Waters D.D. Time to recognize HIV infection as a major cardiovascular risk factor. Circulation. 2018; 138 (11): 1113-5.
23. Hsue P.Y., Waters D.D. HIV infection and coronary heart disease: mechanisms and management. Nat Rev Cardiol. 2019; 16 (12): 745-59. doi: 10.1038/s41569-019-0219-9
24. Bartlett J.G., Redfield R.R., Pham P.A., Mazus A.I. Clinical aspects of HIV infection. Moscow: GRANAT, 2013: 696 p. (in Russian)
25. Losina E., Hyle E.P., Borre E.D., et al. Projecting 10-year, 20-year, and lifetime risks of cardiovascular disease in persons living with human immunodeficiency virus in the United States. J Clin Infect Dis. 2017; 65 (8): 1266-71.
26. Post W.S., Budoff M., Kingsley L., et al. Associations between HIV infection and subclinical coronary atherosclerosis: the Multicenter AIDS Cohort Study (MACS). Ann Intern Med. 2014; 160 (7): 458-67.
27. Pereyra F., Lo J., Triant V.A., et al. Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS. 2012; 26 (18): 2409-12.
28. Kearns A., Gordon J., Burdo T.H., Qin X. HIV-1-associated atherosclerosis: unraveling the missing link. J Am Coll Cardiol. 2017; 69 (25): 3084-98.
29. Paiardini M., Mdller-Trutwin M. HIV-associated chronic immune activation. J Immunol Rev. 2013; 254 (1): 78-101.
30. Sauce D., Larsen M., Fastenackels S., et al. HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood. 2011; 117 (19): 5142-51.
31. Longenecker C.T., Sullivan C., Baker J.V. Immune activation and cardiovascular disease in chronic HIV infection. Curr Opin HIV AIDS. 2016; 11 (2): 216-25.
32. Hunt P.W., Brenchley J., Sinclair E., et al. Relationship between T cell activation and CD4+ T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis. 2008; 197 (1): 126-33.
33. Crowell T.A., Gebo K.A., Blankson J.N., et al. Hospitalization rates and reasons among HIV elite controllers and persons with medically controlled HIV infection. J Infect Dis. 2015; 211 (11): 1692-702.
34. Zicari S., Sessa L., Cotugno N., et al. Immune activation, inflammation, and non-AIDS co-morbidities in HIV-infected patients under long-term ART. Viruses. 2019; 11 (3). doi: 10.3390/v11030200